Sirio Europe Announces New Softgel Formulations

Published on: 

The new products aim to aid consumers with menopause and eye health-related issues.

On Aug 25, 2023, Sirio Europe (SIRIO) announced that it will launch two new pharma-targeted softgels at CPHI Barcelona 2023. The new formulations were created to adhere to the rising demand for products with more natural actives for both menopause and improved eye health. They are part of the company’s strategy to create new nutraceutical combinations in Europe alongside premium over-the-counter (OTC) brands and large pharmacy chains. Sirio created two ready-to-launch concepts for CPHI Barcelona, in an effort to help its partners innovate and move to market faster.

Sirio’s menopause softgel contains evening primrose oil as an appeal to market demands for plant-based products; the softgel is both vegan and gluten free. Each softgel will contain 500mg of evening primrose oil, as well as 45mg of Gamma Linolenic Acid, which Sirio stated is known to help regulation of immunity, cholesterol, and menstrual cycles.

Sirio’s eye health softgel uses a new special vision care complex, which contains a combination of Lutein, Zeaxanthin, and Astaxanthin. These three ingredients, according to Sirio, help maintain eye heath and improve hand-eye coordination. Sirio suggested that the product could prove successful in the growing prosumer market for gamers. This softgel will be available immediately and come with end-to-end service.


Sara Lesina, Sirio’s general manager Europe, added in a Sirio press release: “There is now a global drive towards exceptional quality and the highest manufacturing standards for nutraceuticals. Our ideal partners are those that share these values and are looking to develop products that have enhanced bioavailability, proven shelf life, and critically for a consumer facing product, far better organoleptic qualities.” Sirio plans to showcase their new softgels (as well as a range of gummies) at CPHI Barcelona 2023 in stand 1A30.

Source: Sirio